

Wednesday 9 February 2005			
	Auditorium Stream 1 R&D	Presentation Room II Stream 2 Marketing & Branding	Presentation Room III Stream 3 Manufacturing, Packaging & Logistics
07:30-08:15	Event Registration – marcus evans Registration Desk		
08:15-08:30	marcus evans Opening Address Christian Sorensen , Congress Director, Europe marcus evans Welcome Address Dr Lumir H. Krocěk , Executive Director, CAFF (Czech Republic) Generic Association		
08:30-09:15	Opening Keynote Presentation INTERNATIONAL REGULATIONS AND NATIONAL RULES: HOW DO THEY WORK TOGETHER? <ul style="list-style-type: none"> • Revisions of the European legislative: Impact on the package leaflet in the international and national context • Levels of changes for publicly available information on authorised products? • Changing the business process of all Competent Authorities • Addressing the activities needed to cover the requirements on a European and national level: Germany as a case study Dr Klaus Menges , Director, Clinical Pharmacology II, FEDERAL INSTITUTE FOR DRUGS & MEDICAL DEVICES (BfArM)		
09:15-10:00	Keynote Presentation Stream 1 THE EU DIRECTIVE: IMPLICATIONS FOR CLINICAL RESEARCH, MARKET EFFICIENCY & THE QUEST FOR INNOVATION? <ul style="list-style-type: none"> • The implementation of The EU Directive • Ethics, economics and global trends • The new clinical research environment • Implications for research innovation Dr Keith Bragman , Consulting Physician, Former Director & Head of Global Development, UCB SA	Keynote Presentation Stream 2 MARKETING COMMUNICATIONS FOR PHARMA PRODUCTS: <ul style="list-style-type: none"> • Optimising the effects of synergy • Integrating different marketing strategies • Communicative strategies for pharma • Sales force effectiveness Professor Christo Kaftandjiev , Professor, SOFIA UNIVERSITY , Bulgaria	Keynote Presentation Stream 3 OUTSHINING THE REST AT BOEHRINGER-INGELHEIM, UK <ul style="list-style-type: none"> • Our business • Transformation at Bracknell • Blow fill seal specialist technology • Positioning ourselves Mark Foss , Head of Engineering, BOEHRINGER-INGELHEIM, UK
10:00-10:30	Coffee Break Exhibitor Meetings & Appointments		
10:30-11:15	Case Study Presentation ADMET FIRST IN THE SELECTION OF CANDIDATES TO DEVELOPMENT <ul style="list-style-type: none"> • New approaches for candidate selection • "Classical" vs non-classical pharma • REACH and its impact on safety assessment • In Vitro Testing Industrial Platform Dr Joan-Albert Vericat , Pre-clinical Development Director, NEUROPHARMA SA	Case Study Presentation BRINGING ORPHAN PRODUCTS TO MARKET <ul style="list-style-type: none"> • Definitions of orphan & ultra orphan diseases • Why most orphan diseases lack treatment • The orphan product business model • Reviewing the challenges • Critical success factors for the launch Leanna M. Caron , Head, European Marketing & Business Unit, GENZYME	Case Study Presentation TPM IN A PHARMA PRODUCTION PLANT <ul style="list-style-type: none"> • Implementing TPM • Overcoming organisational obstacles • Change management • Dealing with cultural change Dr Wim Mens , Vice President Production, NV ORGANON

<p>11:15-12:00</p>	<p>Case Study Presentation THE NEW ROLE OF PHARMOCOVIGILANCE IN THE PHARMA INDUSTRY</p> <ul style="list-style-type: none"> • Safety representative's roles and responsibilities • The impact of Eudravigilance • Organising a pharmacovigilance department in your country <p>Dr Dimos Florakis, Medical Manager, ABBOTT LABORATORIES HELLAS SA</p>	<p>Case Study Presentation UNDERSTANDING THE CEE MARKET: GLOBAL VERSUS LOCAL MARKETING STRATEGIES</p> <ul style="list-style-type: none"> • Addressing regional differences: • What do CEE markets really look like? • Identifying trends for future development • Implementing step measures <p>Dr Jasmina Koeva, Head of Marketing, ACTAVIS</p>	<p>Case Study Presentation MANAGING COMPLIANCE IN PHARMACEUTICAL PRODUCTION</p> <ul style="list-style-type: none"> • Measuring operational compliance • Developing compliance assessment • Internal benchmarks in production • Defining site specific compliance paths <p>Dr Wolfgang Steven, Head of Department Integrated Quality Management, SCHERING AG</p>
<p>12:00-13:00</p>	<p>Lunch Exhibitor Meetings & Appointments</p>		
<p>13:00-13:45</p>	<p>Case Study Presentation IMPROVING CLINICAL TRIAL PERFORMANCE AT COUNTRY LEVEL</p> <ul style="list-style-type: none"> • The Success of a clinical trial? • The origin of failures or unsuccessful trials? • Decisions on clinical trials in your country? • What are the lessons for the future? <p>Dr John Shillingford, Managing Director, IMFORM GmbH</p>	<p>Case Study Presentation DTC IN THE HEALTH CARE SECTOR: A THREAT OR A HELPFUL TOOL?</p> <ul style="list-style-type: none"> • Direct To Consumer advertising • Fostering awareness of illness, or harmful in aggressive promotion of misleading claims? • Serving the patient community <p>Marta Wielondek, Senior Project Manager, Sales & Marketing Effectiveness, NOVO NORDISK REGION EUROPE A/S</p>	<p>Case Study Presentation FINDING A SOLUTION THAT BALANCES BUSINESS NEEDS, REGULATORY CRITERIA AND THE SOPHISTICATED REQUIREMENTS OF GRAPHIC ARTS</p> <ul style="list-style-type: none"> • Harmonising artwork management processes • Introducing a new artwork management system across global business • The rationale for change • Issues in introducing the new global labelling system "Gazelle" <p>Steven Burgess, International Project Leader, ASTRAZENECA</p>
<p>13:45-14:30</p>	<p>Roundtable Panel Discussion JOIN KEITH, JOAN-ALBERT, DIMOS AND JOHN, OUR DAY 1 SPEAKERS, TO DISCUSS THE MAIN THEMES OF TODAY'S PRESENTATIONS AND THE FUTURE OF R&D.</p>	<p>Case Study OVERCOMING REGULATORY CHALLENGES IN THE POST-ACCESSION PHARMACEUTICAL MARKET</p> <p>Patent protection law & Future Medicines Legislation Increasing product launches Managing opportunities and threats in the new EU The expected contribution of CEE pharma to the EU</p> <p>Radunka Cvejic, Governmental Affairs Director, ASTRAZENECA Poland</p>	<p>Case Study Presentation RE-ENGINEERING STRATEGIES IN THE SUPPLY CHAIN TO COPE WITH FUTURE TRENDS & CHALLENGES</p> <ul style="list-style-type: none"> • Re-visiting supply chain strategies • Streamlining our organisation • Considerations in the transition phase • Strategic responses & future action <p>Peter Holm Tygesen, Vice President, Pharmaceutical Production SOE, H. LUNDBECK A/S</p>
<p>14:30-15:00</p>	<p>Coffee Break Exhibitor Meetings & Appointments</p>		
<p>15:00-15:45</p>	<p>Keynote Presentation PARALLEL TRADE – DISPELLING THE MYTHS</p> <ul style="list-style-type: none"> • Separating fact from fiction • Common myths about the parallel trade industry • Price harmonisation and the value of parallel trade in the EU • Now and Beyond: The scale of parallel trade in Europe <p>Tomasz Dzitko, President & CEO, DELFARMA, Poland & CEE Member, EUROPEAN ASSOCIATION OF EURO-PHARMACEUTICAL COMPANIES (EAEP)</p>		

15:45-16:30	<p>Keynote Presentation</p> <p>PROTECTING THE INTEGRITY OF MEDICINES TO COUNTER THE GROWING THREAT OF COUNTERFEIT MEDICINES IN THE LEGITIMATE SUPPLY CHAIN</p> <ul style="list-style-type: none"> • New and enhanced regulations & oversight by regulatory authorities • Enhanced business practices by all participants in the supply chain • The use of new technologies • Heightened diligence & increased accountability by ALL in the distribution channel <p>Julian Mount, European Director of Trade, PFIZER INC.</p>
16:30-18:00	Cocktail Reception – Gallery B - Upstairs

Thursday 10 February 2005			
	Auditorium Stream 1 R&D	Presentation Room II Stream 2 Marketing & Branding	Presentation Room III Stream 3 Manufacturing, Packaging & Logistics
08:30-09:15	<p>Keynote Presentation</p> <p>IP RIGHTS – POST EU ACCESSION</p> <ul style="list-style-type: none"> • Definition of IP rights • Harmonisation of IP rights with EU regulations & Directives • Extension of patent monopoly in the pharmaceutical industry <p>Dr Attila Mandi, Head Industrial Property Rights Department, EGIS Pharmaceuticals Ltd.</p>		
09:15-10:00	<p>Keynote Presentation Stream 1</p> <p>BIOTECHNOLOGY IN THE CEE REGION: SPOTLIGHT ON HUNGARY</p> <ul style="list-style-type: none"> • Hungarian biotech companies • Scientific & business environment • Traditions in pharmaceutical sector • Subsidies on patenting <p>Erno Duda, President, HUNGARIAN BIOTECHNOLOGY ASSOCIATION & President & CEO, SOLVO BIOTECHNOLOGY</p>	<p>Keynote Presentation Stream 2</p> <p>SALES FORCE EFFECTIVENESS TO SELL YOUR PRODUCT</p> <ul style="list-style-type: none"> • Re-branding of Novartis generics to Sandoz • Positioning of the corporate brand Sandoz • Key elements of the Sandoz brand • Future outlooks <p>Dr Arnim Jost, Head Global Marketing & Sales Services, SANDOZ GMBH, Austria</p>	<p>Keynote Presentation Stream 3</p> <p>PHARMACEUTICAL PACKAGING - LESSONS AND FUTURE TRENDS</p> <ul style="list-style-type: none"> • Learning from history • The future environment • Implications for packaging <p>Dr Laura Cohen, International Packaging Project Manager UK Operations, ASTRAZENECA & Chairman, UK INSTITUTE OF PACKAGING PHARMACEUTICAL FORUM</p>
10:00-10:30	<p>Coffee Break</p> <p>Exhibitor Meetings & Appointments</p>		
10:30-11:15	<p>Case Study Presentation</p> <p>EXPERIENCES OF SMALL BIOTECH COMPANIES WITH BIG PHARMA IN BUSINESS DEVELOPMENT</p> <ul style="list-style-type: none"> • Identifying target companies • Development of customised strategies • Marketing strategies in drug development • Agreements & timelines for partnering <p>Dr Gerhard Wolff, Director Preclinical and Clinical Development, REVOTAR BIOPHARMACEUTICALS</p>	<p>Case Study Presentation</p> <p>SALES FORCE EFFECTIVENESS AT GRUNENTHAL</p> <p>Gerard Akkerhuis, Head of Area Management Europe, GRUNENTHAL</p>	<p>Case Study Presentation</p> <p>PERFORM & IMPROVE IN ORDER TO COMPLY & SAVE</p> <ul style="list-style-type: none"> • Meeting industry requests in transport • Distribution in the business chain • Balancing multiple parameters • Release your creativity <p>Zeljka Bilos Kovacic, Distribution Manager, PLIVA CROATIA LTD</p>

11:15-12:00	<p>Case Study Presentation</p> <p>CORPORATE LICENSING STRATEGY - PAST AND FUTURE</p> <ul style="list-style-type: none"> • Product in-licensing & launches • Reconstruction of new product franchises • Quality & training of medical representatives • Territory alliances <p>Takefumi Miyamoto, Head of London Office Corporate Licensing, TANABE SEIYAKU CO. LTD.</p>	<p>Case Study Presentation</p> <p>LOCALISATION VERSUS GLOBALISATION: CREATING A BRAND PERSONALITY</p> <ul style="list-style-type: none"> • Research and strong strategic planning • A clear vision of the personality of the brand • Local habits, psychology and motivation • Tradeoffs <p>Dr Elena Magura, Product Manager for Ukraine & Moldova, POLPHARMA S.A.</p>	<p>Case Study Presentation</p> <p>MAJOR QUALITY ISSUES 2005; FROM MANUFACTURER TO SUPPLIER</p> <ul style="list-style-type: none"> • Quality Assurance for Pharma Suppliers • A New Quality: ISO 15378 • Integrating and complementing GMP requirements into ISO 9001 & ISO 9001:2000 <p>Dr Philippe Sempé, retired Senior Manager of Supplier Assurance/Worldwide QA, AVENTIS</p>
12:00-13:00	<p>Lunch</p> <p>Exhibitor Meetings & Appointments</p>		
13:00-13:45	<p>Keynote Presentation</p> <p>THERAPEUTIC INFORMATION DIRECT TO THE CITIZEN: A NEW WAY OF LOOKING AT THE PROBLEM?</p> <ul style="list-style-type: none"> • Advertising Vs. Information • Drugs Sales Online • Comparative Advertising • Therapeutic Information & Responsibility <p>Nuria Amarilla, CEO, EUROPEAN PHARMACEUTICAL LAW GROUP</p>		
13:45-14:30	<p>Closing Keynote Presentation</p> <p>THE CHANGING ROLE OF QUALITY MANAGEMENT</p> <ul style="list-style-type: none"> • Common misunderstandings in QM: Doing things right vs doing the right things • Learning from common audit findings to improve processes and systems in future clinical trials • Aligning QM to the drug development stage: how much of what and when? • Identifying the added value of QM and developing QM into a strategic position <p>Rita Hattemer-Apostel, CEO, VERDANDI AG, Editor-in-Chief, THE QUALITY ASSURANCE JOURNAL, President, SPAQA (Swiss Professional Association of Quality Assurance)</p>		
14:30-14:45	<p>Closing Address</p> <p>Dr Lumir H. Krocek, Executive Director, CAFF (Czech Republic) Generic Association</p>		